Scott Boiko Director of Translational Medicine at Nimbus Therapeutics
live WEBINAR
Shaping drug development with tumor organoids and RWD
TUESDAY, OCTOBER 1
12pm ET / 11am CT / 9am PT
REGISTER NOW
All registrants will be sent the webinar recording shortly following the completion of the session.
what you’ll learn
During this engaging session, you will:
- Discover how Tempus addresses drug development challenges with our extensive 3D patient-derived organoid (PDO) biorepository and real-world data (RWD) platform.
- Explore one of the largest, pan-indication PDO collections in the industry and our fixed screening panels for small molecules, antibody-drug conjugates, cell therapies, and more.
- Learn how these resources can enhance preclinical models and drive more effective drug development.
SPEAKERS
READ BIO
Scott Boiko is currently serving as the Director of Translational Medicine at Nimbus Therapeutics. Prior to this role, Scott held positions at Forma Therapeutics as an Associate Director of Translational Science, and at AstraZeneca in various scientific roles. Scott's educational background includes a Master's Degree in Biological Sciences from the University of Massachusetts Lowell, where Scott also obtained a Bachelor's Degree in the same field.
Richard Klinghoffer, PhDSVP, Head of Systems Biology, Tempus
READ BIO
Rich Klinghoffer, PhD, is the Senior Vice President of Systems Biology and Head of the Modeling Lab at Tempus AI. His team leverages functional screens, multimodal profiling, and a "lab-in-the-loop" approach with real-world data (RWD) to advance the understanding of tumor responses to drug exposure.
Prior to joining Tempus, Rich served as the CEO and Head of Research at Presage Biosciences, a biotechnology company in Seattle focused on translational oncology. At Presage, his team developed the Presage CIVO platform, which, in combination with spatial biology platforms like Nanostring’s GeoMx DSP, enabled the detailed evaluation of multiple drugs and drug combinations within cancer patients' solid tumors. This work introduced a new approach to Phase 0 microdosing trials.
Before Presage, Rich worked in both small biotech and large pharmaceutical settings. At Merck’s Rosetta Inpharmatics, he led a team of scientists dedicated to identifying and validating cancer targets and predictive biomarkers for Merck’s Oncology Franchise.
Rich is the author of over 30 peer-reviewed research papers and holds multiple patents related to cancer drug development technologies. He earned his PhD from the University of Colorado Health Sciences Center and completed a postdoctoral fellowship as a Special Fellow of the Leukemia and Lymphoma Society at the Fred Hutchinson Cancer Research Center.
Michelle Mack, PhDSenior Director of Business Development, Biological Modeling, Tempus
READ BIO
Michelle Mack, PhD is currently Senior Director at Tempus AI, and manages Tempus’ biological modeling business development. Michelle has led commercial teams across several oncology focused service providers over the last 8 years. Additionally, she brings 15 years of previous Oncology R&D experience from Pfizer, where she was a Senior Scientist in the Oncology Research Unit and served as a research project leader on oncology therapeutic programs. At Pfizer, she led cross-functional teams exploring approaches that included small-molecule inhibitors and antibody drug conjugates. Michelle’s scientific expertise span’s the preclinical and translational space for multiple solid and hematological tumor indications across oncology and Immuno-Oncology therapeutic areas. Dr. Mack obtained her undergraduate degree from Rochester Institute of Technology. She then received her Ph.D. in Molecular Biology from Seton Hall University.
